IV infusion 1st infusion: Initially 50 mg/hr. After the 1st 30 min, escalate in 50 mg/hr increments every 30 min to a max 400 mg/hr. Subsequent infusions: Initially 100 mg/hr, increased by 100 mg/hr increments at 30-min intervals to a max 400 mg/hr.
Combination therapy for induction treatment of previously untreated or relapsed/refractory patients w/ follicular non-Hodgkin's lymphoma 375 mg/m
2 per cycle, for up to 8 cycles. Administer on day 1 of each chemotherapy cycle, after IV administration of the glucocorticoid component of the chemotherapy if applicable.
Maintenance therapy for previously untreated follicular lymphoma 375 mg/m
2 once every 2 mth (starting 2 mth after the last dose of induction therapy) until disease progression or for a max period of 2 yr (12 infusions in total).
Maintenance therapy for relapsed/refractory follicular lymphoma 375 mg/m
2 once every 3 mth (starting 3 mth after the last dose of induction therapy) until disease progression or for a max period of 2 yr (8 infusions in total).
Monotherapy as induction treatment for adults w/ stage III-IV follicular lymphoma who are chemoresistant or are in their 2nd or subsequent relapse after chemotherapy 375 mg/m
2 IV infusion once wkly for 4 wk.
Retreatment w/ Rixathon monotherapy in patients who have responded to previous treatment w/ rituximab monotherapy for relapsed/refractory follicular lymphoma 375 mg/m
2 IV infusion once wkly for 4 wk.
Diffuse large B cell non-Hodgkin's lymphoma 375 mg/m
2, administered on day 1 of each chemotherapy cycle for 8 cycles after IV infusion of the glucocorticoid component of CHOP.
Chronic lymphocytic leukaemia 375 mg/m
2 administered on day 0 of the 1st treatment cycle followed by 500 mg/m
2 administered on day 1 of each subsequent cycle for 6 cycles in total. The chemotherapy should be given after Rixathon infusion.
Sign Out
